---
title: "CHENGDA PHARMA issues a profit warning, expecting a net loss of 21 million to 29 million yuan for the fiscal year 2024, turning from profit to loss year-on-year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/225184193.md"
description: "CHENGDA PHARMA expects a net loss of 21 million to 29 million yuan for the year 2024, turning from profit to loss year-on-year. The operating income for the reporting period is expected to decline by 16%-27%, with sales revenue from the raw material drug business decreasing by approximately 33%. Research and development expenses are expected to increase to 90 million to 98 million yuan. Non-recurring gains and losses are expected to impact net profit by approximately 30 million yuan"
datetime: "2025-01-16T10:38:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/225184193.md)
  - [en](https://longbridge.com/en/news/225184193.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/225184193.md)
---

# CHENGDA PHARMA issues a profit warning, expecting a net loss of 21 million to 29 million yuan for the fiscal year 2024, turning from profit to loss year-on-year

According to the Zhitong Finance APP, CHENGDA PHARMA (301201.SZ) disclosed its performance forecast for 2024. The company expects a net loss attributable to shareholders of the listed company in the range of 21 million to 29 million yuan for the reporting period, with a net loss of 50 million to 60 million yuan after deducting non-recurring gains and losses, marking a shift from profit to loss year-on-year.

The operating revenue for the reporting period is expected to decline by approximately 16% to 27% year-on-year. Among them, the sales revenue from the raw material drug business is expected to decrease by about 33% year-on-year, mainly due to the oversupply of pharmaceutical-grade L-carnitine by customers in 2023, leading to a decline in demand during the reporting period; the company's CDMO business has seen a reduction in orders and a decline in sales revenue. In addition, the company's R&D expenses are expected to be around 90 million to 98 million yuan, an increase of approximately 66 million yuan compared to the previous year. It is estimated that the impact of non-recurring gains and losses on the company's net profit for the reporting period will be about 30 million yuan, mainly from government subsidies and cash management investment income recognized in the current period

### Related Stocks

- [301201.CN](https://longbridge.com/en/quote/301201.CN.md)

## Related News & Research

- [Ray Dalio Says US Is in Decline: 'Threats No Longer Work' in a World Where Order Breaks Down](https://longbridge.com/en/news/294556219.md)
- [Is Citadel's Surprise July Rate Hike Call Viable? Jim Bianco Says 38% Market Odds Mean It's 'Not That Far'](https://longbridge.com/en/news/294029822.md)
- [Orion Diversified Holding buys 0.61% working interest in North Dakota Wiley Glenburn Unit](https://longbridge.com/en/news/293955142.md)
- [Muyuan Foods says Stock Exchange disciplinary statement on Redco does not affect director Chow Ming Sang’s duties](https://longbridge.com/en/news/294188255.md)
- [Thyssenkrupp Nucera hands over skid-mounted chlor-alkali plant to Chlorum Solutions in Brazil](https://longbridge.com/en/news/294180764.md)